Last reviewed · How we verify
NCT06173947
SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
trial testing FibroScan® Expert 630 in End Stage Liver Disease in 411 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 411 |
| Start date | 1 January 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- FibroScan® Expert 630
Conditions studied
- End Stage Liver Disease — all drugs for End Stage Liver Disease →
- Jaundice — all drugs for Jaundice →
- Liver Dysfunction — all drugs for Liver Dysfunction →
- Portal Hypertension — all drugs for Portal Hypertension →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 18 to 80, any sex, with End Stage Liver Disease or Jaundice. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06173947
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Liver Disease
Currently open trials in the same condition.
- NCT04496479 — Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes · Phase 2 · recruiting
- NCT02581085 — Tocotrienol Against the Progression of End Stage Liver Disease · Phase 2 · active not recruiting
- NCT06418165 — Vienna Hypothermic Oxygenated Machine Perfusion Study · recruiting
- NCT03803423 — Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors · NA · recruiting
- NCT03228290 — Functional Assessment in Liver Transplantation · recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06173947 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06173947.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing